HTA for pharmaceuticals in Europe: will the mountain deliver a mouse?

Garattini, Livio

doi:10.1007/s10198-019-01103-9

Cited by 5 publications

(2 citation statements)

References 43 publications

(77 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…According to the literature evidence, influenza is responsible for 30% of the total annual burden of the 31 most common infectious diseases in Europe [ 17 ], as influenza virus infections each year cause up to 1.8–3.5 additional hospitalizations per 10,000 persons, with an average cost of 6100–8300 EUR [ 18 ]. Influenza infections not only increase the risk of required hospitalization, but also prolong its duration (which was also demonstrated in the previously analyzed data from the University Hospital in Wrocław) and raise the overall cost of treatment [ 1 ].…”

Section: Discussionmentioning

confidence: 99%

Seasonal Influenza and Low Flu Vaccination Coverage as Important Factors Modifying the Costs and Availability of Hospital Services in Poland: A Retrospective Comparative Study

Susło

Pobrotyn

Brydak

et al. 2021

IJERPH

View full text Add to dashboard Cite

Introduction: Influenza infection is associated with potential serious complications, increased hospitalization rates, and a higher risk of death. Materials and Methods: A retrospective comparative analysis of selected indicators of hospitalization from the University Hospital in Wroclaw, Poland, was carried out on patients with confirmed influenza infection in comparison to a control group randomly selected from among all other patients hospitalized on the respective wards during the 2018–2019 influenza season. Results: The mean laboratory testing costs for the entire hospital were 3.74-fold higher and the mean imaging test costs were 4.02-fold higher for patients with confirmed influenza than for the control group; the hospital expenses were additionally raised by the cost of antiviral therapy, which is striking when compared against the cost of a single flu vaccine. During the 2018–2019 influenza season, influenza infections among the hospital patients temporarily limited the healthcare service availability in the institution, which resulted in reduced admission rates to the departments related to internal medicine; the mean absence among the hospital staff totaled approximately 7 h per employee, despite 7.3% of the staff having been vaccinated against influenza at the hospital’s expense. Conclusions: There were significant differences in the hospitalization indicators between the patients with confirmed influenza and the control group, which markedly increased the hospital care costs in this multi-specialty university hospital.

show abstract

Section: Discussionmentioning

confidence: 99%

Seasonal Influenza and Low Flu Vaccination Coverage as Important Factors Modifying the Costs and Availability of Hospital Services in Poland: A Retrospective Comparative Study

Susło

Pobrotyn

Brydak

et al. 2021

IJERPH

View full text Add to dashboard Cite

show abstract

“…Рано е да се предвиди въздействието на промените по ОЗТ в Италия върху цялостната европейска картина. По всичко изглежда обаче, че италианските здравни власти не разчитат особено на EUnetHTA и на перспективите за общоевропейска процедура по ОЗТ [14]. Напротив, те засилват правомощията на AIFA по отношение на контрола върху цените на лекарствените продукти, което е логично действие.…”

Section: как промените в процедурата по озт в италия ще се отразят в unclassified

Започва Ли Глобална Промяна В Парадигмата За Оценка На Здравните Технологии?

Искров¹,

Стефанов²

2020

Редки болести и лекарства сираци

View full text Add to dashboard Cite

От самото си създаване парадигмата на оценката на здравните технологии (ОЗТ) търпи непрекъсната еволюция. Това е съвсем естествен процес предвид развитието на медицинската наука и ускореното навлизане на иновативни здравни технологии. През последните години се наблюдава обаче все по-ясно изразена тенденция за засилване на прозрачността при ценообразуването и обързване на реимбурсната цена на здравните технологии с тяхната ефективност. На 24 юли 2020 г. Италия официално обнародва нова нормативна уредба за ОЗТ, с което освен друго съществено увеличава публичния контрол върху ценообразуването и заплащането с публични средства на всички нови лекарствени продукти. Настоящата статия има за цел да обобщи и анализира критично най-важното от тези промени и значението им за европейската политика и практика в областта на ОЗТ.

show abstract

Prices of Orphan Drugs in Four Western European Countries Before and After Market Exclusivity Expiry: A Cross-Country Comparison of List Prices and Purchase Prices

Dane,

Klein Gebbink,

Brugma

et al. 2023

Appl Health Econ Health Policy

View full text Add to dashboard Cite

Background Increasing pharmaceutical expenditure challenges the sustainability and accessibility of healthcare systems across Europe. Confidentiality restraints hinder assessment of actual prices of Orphan Medicinal Products (OMPs). Hence, we assessed the real prices of brand-name OMPs around market exclusivity expiry (MEE). Objective We aimed to explore developments in published list prices (LPs) and confidential hospital purchase prices (PPs) of brand-name OMPs relative to their market exclusivity status in Western European countries with similar GDPs. Methods We analyzed LPs and PPs of 13 selected OMPs purchased by university hospitals in Western European countries between 2000 and 2020. For confidentially reasons, proportions were used, with the Dutch LPs of the selected OMPs at the year of MEE serving as reference values. PPs included pre-purchase discounts. Rebates were not considered. Results Data were analyzed from hospitals in Denmark (DK) ( n = 1), France (FR) ( n = 1), Germany (DE) ( n = 2), and the Netherlands (NL) ( n = 1). Average LPs and PPs of included OMPs dropped gradually but limited over time, with no explicit price drop after MEE. LP levels differed more per country than PP levels: LP range before MEE was 164% (DE)–101% (FR) and after MEE was 135% (DE)–82% (FR); PP range before MEE was 150% (DE)–102% (FR) and after MEE was 107% (DE)–80% (FR). Overall differences between LPs and PPs were < 3% in all countries, except for Denmark. Conclusion No evident price drops of included brand-name OMPs were observed around MEE and differences in purchase prices are modest in the selected Western European countries. Results were not subject to significance testing. More robust data are needed to strengthen negotiations with suppliers. Supplementary Information The online version contains supplementary material available at 10.1007/s40258-023-00832-6.

show abstract

HTA for pharmaceuticals in Europe: will the mountain deliver a mouse?

Cited by 5 publications

References 43 publications

Seasonal Influenza and Low Flu Vaccination Coverage as Important Factors Modifying the Costs and Availability of Hospital Services in Poland: A Retrospective Comparative Study

Seasonal Influenza and Low Flu Vaccination Coverage as Important Factors Modifying the Costs and Availability of Hospital Services in Poland: A Retrospective Comparative Study

Започва Ли Глобална Промяна В Парадигмата За Оценка На Здравните Технологии?

Prices of Orphan Drugs in Four Western European Countries Before and After Market Exclusivity Expiry: A Cross-Country Comparison of List Prices and Purchase Prices

Contact Info

Product

Resources

About